iQur Board of Directors

Jack B Boyer
William Rosenberg
Bruce Campbell
Brenda Reynolds
Dr John Tite

Jack B Boyer
Non-Executive Chairman

Mr Boyer joined iQur as Chairman in 2004. He previously founded and was the CEO of Trident Components Group, a €280 million revenue pan-European engineering group. Prior to that he was Chair and/or CEO of companies in the manufacturing sector and worked at Goldman Sachs and Bain & Co. He was educated at Stanford University (B.A. Hons), the London School of Economics (M.Sc.) and INSEAD (MBA). Mr Boyer leads the University of Southampton’s corporate spin-out and intellectual property exploitation activities as Chair of Southampton Asset Management and is a non-executive Chairman of early-stage companies in emerging technologies. He is also a Trustee of environmental and educational non-profit organizations.

Professor William Rosenberg
Founder, Chief Scientific Officer and Chief Executive Officer

William Rosenberg was educated at the University of Cambridge and Guy’s Hospital, London, qualifying in medicine in 1983. His early medical training was at the MRC-CRC in Northwick Park, London, before moving to Oxford as a clinical registrar in 1987. In 1988 he entered John Bell’s laboratory in The Institute of Molecular Medicine as a Wellcome Trust Clinical Research Training Fellow.

After completing his DPhil, he returned to clinical work, as Clinical Tutor in Medicine in the University of Oxford, a post he held for five years. In this role William completed his clinical training in gastroenterology, hepatology and general medicine, led an MRC funded research group involved in molecular and immunological science, and gained extensive experience in clinical research and medical education.

In 1997, William moved to Southampton with the remit of developing a service for hepatitis C. Over the last seven years, his group has grown to span epidemiology, clinical research, and basic science. Founded on IP emerging from this basic science research, he began iQur Ltd, the first spin-out company within the School of Medicine at the University of Southampton.

He was Professor of Hepatology in the University of Southampton, and chaired the School of Medicine Liver Group. William became Director of the Wellcome Trust Clinical Research Facility in 2003, and took up Directorship of the Southampton University NHS Trust R&D office in 2005. In 2006 he became Associate Director for Experimental Medicine in the UK Clinical Research Network (UKCRN).

William Rosenberg currently holds the Richard Cristin Chair of Hepatology University College London and Joint Head of Centre for Hepatology University College London. 

He is Director of the UCLH/UCL Clinical Research Facility incorporating the Wellcome Trust CRF and Cancer CRF. He is also Lead for Viral Hepatitis and Consultant Hepatologist, UCLH Foundation NHS Trust and Consultant Hepatologist, Royal Free Hampstead NHS Trust

His national work with the NIHR involves co-ordination of translational research and the development of links between the NHS, Industry and Academia.

His main research interests are in the immunology of viral hepatitis and biomarkers of chronic liver disease.

Professor Rosenberg was appointed CEO of iQur in February 2007.

Dr Bruce Campbell
Non-Executive Director

Bruce Campbell joined iQur Ltd in 2005. He is also the non-executive Chairman of Proximagen Neuroscience plc, Chief Scientific Officer and a director of IP2IPO Group plc, a director of Modern Biosciences plc and a non-executive director of Synairgen plc and Proximagen Ltd.

Formerly, Dr Campbell was Senior VP of International Development at Neurocrine Biosciences, Inc. Prior to joining this NASDAQ listed biotechnology company, Dr Campbell worked for 27 years at Servier (United Kingdom), latterly as Scientific Director. In addition, he has also been a director and European Chairman of the Drug Information Association and a member of the European ICH Safety Working Party.

Dr Campbell is a visiting Professor in Pharmacology at King’s College, London. He has specific expertise on the practical and regulatory aspects of clinical pharmacology, pharmacokinetics, metabolism and toxicology in new drug development and has written standard texts on these subjects and published more than 100 scientific papers.

Brenda Reynolds
Non-Executive Director

In addition to her non-executive director roles at iQur and D3Tex, Brenda Reynolds is currently Chief Operating Officer of Convergence Pharmacueticals Ltd, a Pain Therapeutics biotech company that has recently raised £22.4 million from Euripean and US VCs.  She is also  an independent consultant to other Biotech companies via her company Questrax Ltd.. She was a founder of PowderMed Ltd in May 2004 and was Chief Operating Officer from its inception through to its sale to Pfizer in December 2006. 

As Vice President of Portfolio and Programme Management at Powderject Holdings PLC she had Global responsibility for Portfolio Design and management, ensuring that all projects and their objectives were strategically aligned, subsequently recommending and implementing a business refocus on Vaccines. Previous to this, Brenda held a number of positions across the Healthcare sector. As Programme manager for Sexual Health at Pfizer she was responsible for the Viagra franchise. Previous to this she was a Director of Scotia Holdings PLC holding a number of positions there including Business Director for Oncology, developing a new photodynamic agent and laser system, Managing Director of an Animal Health business, which she subsequently divested, and Director of Preclinical Development.  

Dr John Tite
Non-Executive Director

John graduated with a First Class Honours degree in Zoology from University College London before completing a PhD in Immunology at the Middlesex Hospital Medical School. After post-doctoral training at Yale University Medical School, John returned to the United Kingdom to take up the position of research scientist at the Wellcome Foundation working on the development of the first humanised therapeutic antibody–CAMPATH-1H. He has been involved in the discovery and development of therapeutic antibodies and vaccines since that time and played a key role in the establishment of GSK’s Biopharm CEDD. He also led the strategic alliance with PowderJect on DNA vaccines and was the Chairman of the Board for the Edward Jenner Institute for Vaccine Research. John is a frequent contributor to MRC and CR-UK review panels and is currently a member of the MRC-Technology Scientific Advisory Board.